Concept Medical
Concept Medical has initiated the “MAGICAL-ISR” IDE clinical study in the US, utilizing the MagicTouch Sirolimus drug-coated balloon (DCB) for in-stent restenosis (ISR) management.
The study, granted ‘Breakthrough Device’ designation and FDA Investigational Device Exemption (IDE) approval, aims to evaluate the safety and efficacy of MagicTouch in treating ISR. Led by renowned physicians, the study focuses on patients avoiding Target Lesion Failure (TLF) within one year post-procedure.
MagicTouch offers controlled Sirolimus release without permanent scaffold implantation, marking a significant advancement in coronary intervention. This development reflects Concept Medical’s commitment to innovation and patient care.
Dr Manish Doshi, Founder & Managing Director of Concept Medical says, “The MagicTouch technology has been embraced globally, and its entry into the US market through this study, represents a critical step towards addressing the unmet needs in ISR treatment. Our commitment to innovation and patient safety is unwavering, and we anticipate this study will significantly impact how ISR is treated worldwide.”
Read More Business News
KPJ Healthcare is advancing its health system by expanding the use of artificial intelligence in…
Malaysia’s total trade reached RM3.1 trillion in 2025, with Penang emerging as the top exporting…
Petronas is set to explore what is believed to be the world’s second largest gas…
Trip.com Group and Visa have formed a strategic partnership to deliver personalized travel experiences, seamless…
Royalton and Kinara Energy have formalized a Sabah partnership to expand corrosion protection services, strengthen…
Eight people are feared dead after a U.S. Air Force B-52 bomber crashed shortly after…
This website uses cookies.
